Influenza, a One Health paradigm-Novel therapeutic strategies to fight a zoonotic pathogen with pandemic potential

International Journal of Medical Microbiology

Volumn 304, Issue 7, 2014, Pages 894-901

  Ludwig, Stephan ^a   Zell, Roland ^b   Schwemmle, Martin ^c   Herold, Susanne ^d  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

Antiviral therapy; Immune modulation; Influenza virus; One Health; Polymerase complex; Signal transduction

Indexed keywords

ANTIVIRUS AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; OSELTAMIVIR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; VIRUS NUCLEOPROTEIN; ZANAMIVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL (TOPIC); HUMAN; INFLUENZA; INFLUENZA VIRUS; INTRACELLULAR TRANSPORT; NONHUMAN; PANDEMIC; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN PROTEIN INTERACTION; SHORT SURVEY; VETERINARY MEDICINE; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS VIRULENCE;

EID: 84940164771     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2014.08.016     Document Type: Short Survey

References (99)

1. Amorim M.J., Kao R.Y., Digard P. Nucleozin targets cytoplasmic trafficking of viral ribonucleoprotein-Rab11 complexes in influenza A virus infection. J. Virol. 2013, 87:4694-4703.
2. Antoniak S., Owens A.P., Baunacke M., Williams J.C., Lee R.D., Weithauser A., Sheridan P.A., Malz R., Luyendyk J.P., Esserman D.A., Trejo J., Kirchhofer D., Blaxall B.C., Pawlinski R., Beck M.A., Rauch U., Mackman N. PAR-1 contributes to the innate immune response during viral infection. J. Clin. Invest. 2013, 123:1310-1322.
3. Aoki F.Y., Boivin G., Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir. Ther. 2007, 12:603-616.
4. Bennett A.L., Smith D.W., Cummins M.J., Jacoby P.A., Cummins J.M., Beilharz M.W. Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year. Influenza Other Respir. Viruses 2013, 7:854-862.
5. Beyleveld G., White K.M., Ayllon J., Shaw M.L. New-generation screening assays for the detection of anti-influenza compounds targeting viral and host functions. Antiviral Res. 2013, 100:120-132.
6. Borgeling Y., Schmolke M., Viemann D., Nordhoff C., Roth J., Ludwig S. Inhibition of p38 mitogen-activated protein kinase impairs influenza virus-induced primary and secondary host gene responses and protects mice from lethal H5N1 infection. J. Biol. Chem. 2014, 289:13-27.
7. Bright R.A., Shay D.K., Shu B., Cox N.J., Klimov A.I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006, 295:891-894.
8. Cakarova L., Marsh L.M., Wilhelm J., Mayer K., Grimminger F., Seeger W., Lohmeyer J., Herold S. Macrophage tumor necrosis factor-alpha induces epithelial expression of granulocyte-macrophage colony-stimulating factor: impact on alveolar epithelial repair. Am. J. Respir. Crit. Care Med. 2009, 180:521-532.
9. Chenavas S., Crepin T., Delmas B., Ruigrok R.W., Slama-Schwok A. Influenza virus nucleoprotein: structure, RNA binding, oligomerization and antiviral drug target. Future Microbiol. 2013, 8:1537-1545.
10. Chu W.M., Ostertag D., Li Z.W., Chang L., Chen Y., Hu Y., Williams B., Perrault J., Karin M. JNK2 and IKKbeta are required for activating the innate response to viral infection. Immunology 1999, 11:721-731.
11. Cohen P. Protein kinases - the major drug targets of the twenty-first century?. Nat. Rev. Drug Discov. 2002, 1:309-315.
12. Crusat M., de Jong M.D. Neuraminidase inhibitors and their role in avian and pandemic influenza. Antivir. Ther. 2007, 12:593-602.
13. De Clercq E. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. Biochem. Pharmacol. 2007, 73:911-922.
14. De Marco M.A., Porru S., Cordioli P., Cesana B.M., Moreno A., Calzoletti L., Bonfanti L., Boni A., Di Carlo A.S., Arici C., Carta A., Castrucci M.R., Donatelli I., Tomao P., Peri V.M., Di Trani L., Vonesch N. Evidence of cross-reactive immunity to 2009 pandemic influenza A virus in workers seropositive to swine H1N1 influenza viruses circulating in Italy. PLoS ONE 2013, 8:e57576.
15. Dias A., Bouvier D., Crepin T., McCarthy A.A., Hart D.J., Baudin F., Cusack S., Ruigrok R.W. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 2009, 458:914-918.
16. Droebner K., Pleschka S., Ludwig S., Planz O. Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo. Antiviral Res. 2011, 92:195-203.
17. Dürrwald R., Krumbholz A., Baumgarte S., Schlegel M., Vahlenkamp T.W., Selbitz H.J., Wutzler P., Zell R. Swine influenza A vaccines, pandemic (H1N1) 2009 virus, and crossreactivity. Emerg. Infect. Dis. 2010, 16:1029-1030.
18. Ehrhardt C., Ludwig S. A new player in a deadly game: influenza viruses and the PI3K/Akt signalling pathway. Cell. Microbiol. 2009, 11:863-871.
19. Ehrhardt C., Ruckle A., Hrincius E.R., Haasbach E., Anhlan D., Ahmann K., Banning C., Reiling S.J., Kuhn J., Strobl S., Vitt D., Leban J., Planz O., Ludwig S. The NF-kappaB inhibitor SC75741 efficiently blocks influenza virus propagation and confers a high barrier for development of viral resistance. Cell. Microbiol. 2013, 15:1198-1211.
20. Faleiro L., Lazebnik Y. Caspases disrupt the nuclear-cytoplasmic barrier. J. Cell Biol. 2000, 151:951-959.
21. Feld M., Shpacovitch V.M., Ehrhardt C., Kerkhoff C., Hollenberg M.D., Vergnolle N., Ludwig S., Steinhoff M. Agonists of proteinase-activated receptor-2 enhance IFN-gamma-inducible effects on human monocytes: role in influenza A infection. J. Immunol. 2008, 180:6903-6910.
22. Furuta Y., Gowen B.B., Takahashi K., Shiraki K., Smee D.F., Barnard D.L. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013, 100:446-454.
23. Gerritz S.W., Cianci C., Kim S., Pearce B.C., Deminie C., Discotto L., McAuliffe B., Minassian B.F., Shi S., Zhu S., Zhai W., Pendri A., Li G., Poss M.A., Edavettal S., McDonnell P.A., Lewis H.A., Maskos K., Mortl M., Kiefersauer R., Steinbacher S., Baldwin E.T., Metzler W., Bryson J., Healy M.D., Philip T., Zoeckler M., Schartman R., Sinz M., Leyva-Grado V.H., Hoffmann H.H., Langley D.R., Meanwell N.A., Krystal M. Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:15366-15371.
24. Gerloff N.A., Kremer J.R., Charpentier E., Sausy A., Olinger C.M., Weicherding P., Schuh J., Van Reeth K., Muller C.P. Swine influenza virus antibodies in humans, western Europe. Emerg. Infect. Dis. 2009, 17:403-411.
25. Ghanem A., Mayer D., Chase G., Tegge W., Frank R., Kochs G., Garcia-Sastre A., Schwemmle M. Peptide-mediated interference with influenza A virus polymerase. J. Virol. 2007, 81:7801-7804.
26. Guilligay D., Tarendeau F., Resa-Infante P., Coloma R., Crepin T., Sehr P., Lewis J., Ruigrok R.W., Ortin J., Hart D.J., Cusack S. The structural basis for cap binding by influenza virus polymerase subunit PB2. Nat. Struct. Mol. Biol. 2008, 15:500-506.
27. Haasbach E., Hartmayer C., Planz O. Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro. Antiviral Res. 2013, 98:319-324.
28. Haasbach E., Reiling S.J., Ehrhardt C., Droebner K., Ruckle A., Hrincius E.R., Leban J., Strobl S., Vitt D., Ludwig S., Planz O. The NF-kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virus. Antiviral Res. 2013, 99:336-344.
29. He X., Zhou J., Bartlam M., Zhang R., Ma J., Lou Z., Li X., Li J., Joachimiak A., Zeng Z., Ge R., Rao Z., Liu Y. Crystal structure of the polymerase PA(C)-PB1(N) complex from an avian influenza H5N1 virus. Nature 2008, 454:1123-1126.
30. Herold S., Hoegner K., Vadasz I., Gessler T., Wilhelm J., Mayer K., Morty R.E., Walmrath H.D., Seeger W., Lohmeyer J. Inhaled granulocyte/macrophage colony-stimulating factor as treatment of pneumonia-associated acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 2014, 189:609-611.
31. Högner K., Wolff T., Pleschka S., Plog S., Gruber A.D., Kalinke U., Walmrath H.D., Bodner J., Gattenlöhner S., Lewe-Schlosser P., Matrosovich M., Seeger W., Lohmeyer J., Herold S. Macrophage-expressed IFN-β contributes to apoptotic alveolar epithelial cell injury in severe influenza virus pneumonia. PLoS Pathog. 2013, 9:e1003188.
32. Huang F.F., Barnes P.F., Feng Y., Donis R., Chroneos Z.C., Idell S., Allen T., Perez D.R., Whitsett J.A., Dunussi-Joannopoulos K., Shams H. GM-CSF in the lung protects against lethal influenza infection. Am. J. Respir. Crit. Care Med. 2011, 184:259-268.
33. Jefferson T., Jones M., Doshi P., Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 2009, 339:b5106.
34. Jefferson T., Jones M.A., Doshi P., Del Mar C.B., Hama R., Thompson M.J., Spencer E.A., Onakpoya I., Mahtani K.R., Nunan D., Howick J., Heneghan C.J. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014, 4:CD008965.
35. Kao R.Y., Yang D., Lau L.S., Tsui W.H., Hu L., Dai J., Chan M.P., Chan C.M., Wang P., Zheng B.J., Sun J., Huang J.D., Madar J., Chen G., Chen H., Guan Y., Yuen K.Y. Identification of influenza A nucleoprotein as an antiviral target. Nat. Biotechnol. 2010, 28:600-605.
36. Khoufache K., Berri F., Nacken W., Vogel A.B., Delenne M., Camerer E., Coughlin S.R., Carmeliet P., Lina B., Rimmelzwaan G.F., Planz O., Ludwig S., Riteau B. PAR1 contributes to influenza A virus pathogenicity in mice. J. Clin. Invest. 2013, 123:206-214.
37. Khoufache K., LeBouder F., Morello E., Laurent F., Riffault S., Andrade-Gordon P., Boullier S., Rousset P., Vergnolle N., Riteau B. Protective role for protease-activated receptor-2 against influenza virus pathogenesis via an IFN-gamma-dependent pathway. J. Immunol. 2009, 182:7795-7802.
38. Kiso M., Mitamura K., Sakai-Tagawa Y., Shiraishi K., Kawakami C., Kimura K., Hayden F.G., Sugaya N., Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004, 364:759-765.
39. Kolocouris A., Tzitzoglaki C., Johnson F.B., Zell R., Wright A.K., Cross T.A., Tietjen I., Fedida D., Busath D.D. Aminoadamantanes with Persistent in Vitro Efficacy against H1N1 (2009) Influenza A. J. Med. Chem. 2014, 57:4629-4639.
40. Kowalinski E., Zubieta C., Wolkerstorfer A., Szolar O.H., Ruigrok R.W., Cusack S. Structural analysis of specific metal chelating inhibitor binding to the endonuclease domain of influenza pH1N1 (2009) polymerase. PLoS Pathog. 2012, 8:e1002831.
41. Kramer A., Liashkovich I., Oberleithner H., Ludwig S., Mazur I., Shahin V. Apoptosis leads to a degradation of vital components of active nuclear transport and a dissociation of the nuclear lamina. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:11236-11241.
42. Krumbholz A., Lange J., Dürrwald R., Hoyer H., Bengsch S., Wutzler P., Zell R. Prevalence of antibodies to swine influenza viruses in humans with occupational exposure to pigs, Thuringia, Germany, 2008-2009. J. Med. Virol. 2010, 82:1617-1625.
43. Krumbholz A., Lange J., Dürrwald R., Walther M., Müller T.H., Kühnel D., Wutzler P., Sauerbrei A., Zell R. Prevalence of antibodies to European porcine influenza viruses in humans living in high pig density areas of Germany. Med. Microbiol. Immunol. 2013, 203:13-24.
44. Kugel D., Kochs G., Obojes K., Roth J., Kobinger G.P., Kobasa D., Haller O., Staeheli P., von Messling V. Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets. J. Virol. 2009, 83:3843-3851.
45. Kumar N., Xin Z.T., Liang Y., Ly H., Liang Y. NF-kappaB signaling differentially regulates influenza virus RNA synthesis. J. Virol. 2008, 82:9880-9889.
46. Lackenby A., Thompson C.I., Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Curr. Opin. Infect. Dis. 2008, 21:626-638.
47. Lange J., Groth M., Schlegel M., Krumbholz A., Wieczorek K., Ulrich R., Köppen S., Schulz K., Appl D., Selbitz H.J., Sauerbrei A., Platzer M., Zell R., Dürrwald R. Reassortants of the pandemic (H1N1) 2009 virus and establishment of a novel porcine H1N2 influenza virus, lineage in Germany. Vet. Microbiol. 2013, 167:345-356.
48. Liu J., Xiao H., Wu Y., Liu D., Qi X., Shi Y., Gao G.F. H7N9: a low pathogenic avian influenza A virus infecting humans. Curr. Opin. Virol. 2014, 5C:91-97.
49. Ludwig S. Influenza viruses and MAP kinase cascades - novel targets for antiviral therapy?. Signal Transduct. 2007, 7:81-88.
50. Ludwig S., Planz O. Influenza viruses and the NF-kappaB signaling pathway - towards a novel concept of antiviral therapy. Biol. Chem. 2008, 389:1307-1312.
51. Ludwig S., Planz O., Pleschka S., Wolff T. Influenza virus induced signaling pathways - targets for antiviral therapy?. Trends Mol. Med. 2003, 9:46-51.
52. Ludwig S., Pleschka S., Planz O., Wolff T. Ringing the alarm bells: signalling and apoptosis in influenza virus infected cells. Cell. Microbiol. 2006, 8:375-386.
53. Ludwig S., Wang X., Ehrhardt C., Zheng H., Donelan N., Planz O., Pleschka S., Garcia-Sastre A., Heins G., Wolff T. The influenza A virus NS1 protein inhibits activation of Jun N-terminal kinase and AP-1 transcription factors. J. Virol. 2002, 76:11166-11171.
54. Ludwig S., Wolff T., Ehrhardt C., Wurzer W.J., Reinhardt J., Planz O., Pleschka S. MEK inhibition impairs influenza B virus propagation without emergence of resistant variants. FEBS Lett. 2004, 561:37-43.
55. Marjuki H., Alam M.I., Ehrhardt C., Wagner R., Planz O., Klenk H.D., Ludwig S., Pleschka S. Membrane accumulation of influenza A virus hemagglutinin triggers nuclear export of the viral genome via protein kinase Calpha-mediated activation of ERK signaling. J. Biol. Chem. 2006, 281:16707-16715.
56. Matute-Bello G., Liles W.C., Radella F., 2nd, Steinberg K.P., Ruzinski J.T., Hudson L.D., Martin T.R. Modulation of neutrophil apoptosis by granulocyte colony-stimulating factor and granulocyte/macrophage colony-stimulating factor during the course of acute respiratory distress syndrome. Critic. care Med. 2000, 28:1-7.
57. Mazur I., Wurzer W.J., Ehrhardt C., Pleschka S., Puthavathana P., Silberzahn T., Wolff T., Planz O., Ludwig S. Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity. Cell. Microbiol. 2007, 9:1683-1694.
58. Muratore G., Goracci L., Mercorelli B., Foeglein A., Digard P., Cruciani G., Palu G., Loregian A. Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:6247-6252.
59. Nacken W., Ehrhardt C., Ludwig S. Small molecule inhibitors of the c-Jun N-terminal kinase (JNK) possess antiviral activity against highly pathogenic avian and human pandemic influenza A viruses. Biol. Chem. 2012, 393:525-534.
60. Nacken W., Anhlan D., Hrincius E.R., Mostafa A., Wolff T., Sadewasser A., Pleschka S., Ehrhardt C., Ludwig S. Activation of c-jun N-Terminal Kinase upon Influenza A Virus (IAV) Infection Is Independent of Pathogen-Related Receptors but Dependent on Amino Acid Sequence Variations of IAV NS1. J. Virol. 2014, 88:8843-8852.
61. Nimmerjahn F., Dudziak D., Dirmeier U., Hobom G., Riedel A., Schlee M., Staudt L.M., Rosenwald A., Behrends U., Bornkamm G.W., Mautner J. Active NF-kappaB signalling is a prerequisite for influenza virus infection. J. Gen. Virol. 2004, 85:2347-2356.
62. Obayashi E., Yoshida H., Kawai F., Shibayama N., Kawaguchi A., Nagata K., Tame J.R., Park S.Y. The structural basis for an essential subunit interaction in influenza virus RNA polymerase. Nature 2008, 454:1127-1131.
63. Olschlager V., Pleschka S., Fischer T., Rziha H.J., Wurzer W., Stitz L., Rapp U.R., Ludwig S., Planz O. Lung-specific expression of active Raf kinase results in increased mortality of influenza A virus-infected mice. Oncogene 2004, 23:6639-6646.
64. Oxford J.S., Novelli P., Sefton A., Lambkin R. New millennium antivirals against pandemic and epidemic influenza: the neuraminidase inhibitors. Antivir. Chem. Chemother. 2002, 13:205-217.
65. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6853-6866.
66. Pauli E.K., Schmolke M., Wolff T., Viemann D., Roth J., Bode J.G., Ludwig S. Influenza A virus inhibits type I IFN signaling via NF-kappaB-dependent induction of SOCS-3 expression. PLoS Pathog. 2008, 4:e1000196.
67. Pinto L.H., Lamb R.A. The M2 proton channels of influenza A and B viruses. J. Biol. Chem. 2006, 281:8997-9000.
68. Pinto L.H., Lamb R.A. Controlling influenza virus replication by inhibiting its proton channel. Mol. Biosyst. 2007, 3:18-23.
69. Pinto R., Herold S., Cakarova L., Hoegner K., Lohmeyer J., Planz O., Pleschka S. Inhibition of influenza virus-induced NF-kappaB and Raf/MEK/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo. Antiviral Res. 2011, 92:45-56.
70. Planz O. Development of cellular signaling pathway inhibitors as new antivirals against influenza. Antiviral Res. 2013, 98:457-468.
71. Planz O., Pleschka S., Ludwig S. MEK-specific inhibitor U0126 blocks spread of Borna disease virus in cultured cells. J. Virol. 2001, 75:4871-4877.
72. Pleschka S., Wolff T., Ehrhardt C., Hobom G., Planz O., Rapp U.R., Ludwig S. Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat. Cell Biol. 2001, 3:301-305.
73. Presneill J.J., Harris T., Stewart A.G., Cade J.F., Wilson J.W. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am. J. Respir. Crit. Care Med. 2002, 166:138-143.
74. Reuther P., Manz B., Brunotte L., Schwemmle M., Wunderlich K. Targeting of the influenza A virus polymerase PB1-PB2 interface indicates strain-specific assembly differences. J. Virol. 2011, 85:13298-13309.
75. Rey-Carrizo M., Barniol-Xicota M., Ma C., Frigolé-Vivas M., Torres E., Naesens L., Llabrés S., Juárez-Jiménez J., Luque F.J., DeGrado W.F., Lamb R.A., Pinto L.H., Vázquez S. Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus. J. Med. Chem. 2014, 57:5738-5747.
76. Schmolke M., Viemann D., Roth J., Ludwig S. Essential impact of NF-kappaB signaling on the H5N1 influenza A virus-induced transcriptome. J. Immunol. 2009, 183:5180-5189.
77. Sebolt-Leopold J.S., Dudley D.T., Herrera R., Van Becelaere K., Wiland A., Gowan R.C., Tecle H., Barrett S.D., Bridges A., Przybranowski S., Leopold W.R., Saltiel A.R. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. 1999, 5:810-816.
78. Shen Y.F., Chen Y.H., Chu S.Y., Lin M.I., Hsu H.T., Wu P.Y., Wu C.J., Liu H.W., Lin F.Y., Lin G., Hsu P.H., Yang A.S., Cheng Y.S., Wu Y.T., Wong C.H., Tsai M.D. E339. R416 salt bridge of nucleoprotein as a feasible target for influenza virus inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:16515-16520.
79. Shpacovitch V.M., Feld M., Holzinger D., Kido M., Hollenberg M.D., Levi-Schaffer F., Vergnolle N., Ludwig S., Roth J., Luger T., Steinhoff M. Role of proteinase-activated receptor-2 in anti-bacterial and immunomodulatory effects of interferon-gamma on human neutrophils and monocytes. Immunology 2011, 133:329-339.
80. Standiford L.R., Standiford T.J., Newstead M.J., Zeng X., Ballinger M.N., Kovach M.A., Reka A.K., Bhan U. TLR4-dependent GM-CSF protects against lung injury in Gram-negative bacterial pneumonia. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012, 302:L447-L454.
81. Steinwede K., Tempelhof O., Bolte K., Maus R., Bohling J., Ueberberg B., Langer F., Christman J.W., Paton J.C., Ask K., Maharaj S., Kolb M., Gauldie J., Welte T., Maus U.A. Local delivery of GM-CSF protects mice from lethal pneumococcal pneumonia. J. Immunol. 2011, 187:5346-5356.
82. Sturrock A., Seedahmed E., Mir-Kasimov M., Boltax J., McManus M.L., Paine R. GM-CSF provides autocrine protection for murine alveolar epithelial cells from oxidant-induced mitochondrial injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012, 302:L343-L351.
83. Sugiyama K., Obayashi E., Kawaguchi A., Suzuki Y., Tame J.R., Nagata K., Park S.Y. Structural insight into the essential PB1-PB2 subunit contact of the influenza virus RNA polymerase. EMBO J. 2009, 28:1803-1811.
84. Thorlund K., Awad T., Boivin G., Thabane L. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect. Dis. 2011, 11:134.
85. Turrell L., Lyall J.W., Tiley L.S., Fodor E., Vreede F.T. The role and assembly mechanism of nucleoprotein in influenza A virus ribonucleoprotein complexes. Nat. Comm. 2013, 4:1591.
86. Unkel B., Hoegner K., Clausen B.E., Lewe-Schlosser P., Bodner J., Gattenloehner S., Janssen H., Seeger W., Lohmeyer J., Herold S. Alveolar epithelial cells orchestrate DC function in murine viral pneumonia. J. Clin. Investig. 2012, 122:3652-3664.
87. Viemann D., Schmolke M., Lueken A., Boergeling Y., Friesenhagen J., Wittkowski H., Ludwig S., Roth J. H5N1 virus activates signaling pathways in human endothelial cells resulting in a specific imbalanced inflammatory response. J. Immunol. 2011, 186:164-173.
88. Wang J., Wu Y., Ma C., Fiorin G., Wang J., Pinto L.H., Lamb R.A., Klein M.L., Degrado W.F. Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:1315-1320.
89. Watanabe Y., Ibrahim M.S., Suzuki Y., Ikuta K. The changing nature of avian influenza A virus (H5N1). Trends Microbiol. 2012, 20:11-20.
90. Widmann C., Gibson S., Jarpe M.B., Johnson G.L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol. Rev. 1999, 79:143-180.
91. Wunderlich K., Juozapaitis M., Manz B., Mayer D., Gotz V., Zohner A., Wolff T., Schwemmle M., Martin A. Limited compatibility of polymerase subunit interactions in influenza A and B viruses. J. Biol. Chem. 2010, 285:16704-16712.
92. Wunderlich K., Juozapaitis M., Ranadheera C., Kessler U., Martin A., Eisel J., Beutling U., Frank R., Schwemmle M. Identification of high-affinity PB1-derived peptides with enhanced affinity to the PA protein of influenza A virus polymerase. Antimicrob. Agents Chemother. 2011, 55:696-702.
93. Wunderlich K., Mayer D., Ranadheera C., Holler A.S., Manz B., Martin A., Chase G., Tegge W., Frank R., Kessler U., Schwemmle M. Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. PLoS ONE 2009, 4:e7517.
94. Wurzer W.J., Ehrhardt C., Pleschka S., Berberich-Siebelt F., Wolff T., Walczak H., Planz O., Ludwig S. NF-kappaB-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas/FasL is crucial for efficient influenza virus propagation. J. Biol. Chem. 2004, 279:30931-30937.
95. Wurzer W.J., Planz O., Ehrhardt C., Giner M., Silberzahn T., Pleschka S., Ludwig S. Caspase 3 activation is essential for efficient influenza virus propagation. EMBO J. 2003, 22:2717-2728.
96. Yin M.J., Yamamoto Y., Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998, 396:77-80.
97. York I., Donis R.O. The 2009 pandemic influenza virus: where did it come from, where is it now, and where is it going?. Curr. Top. Microbiol. Immunol. 2013, 370:241-257.
98. Yuan P., Bartlam M., Lou Z., Chen S., Zhou J., He X., Lv Z., Ge R., Li X., Deng T., Fodor E., Rao Z., Liu Y. Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site. Nature 2009, 458:909-913.
99. Zell R., Scholtissek C., Ludwig S. Genetics, evolution, and the zoonotic capacity of European Swine influenza viruses. Curr. Top. Microbiol. Immunol. 2013, 370:29-55.